Merck is taking significant steps to ensure global access to a promising new H.I.V. prevention pill. This initiative aims to make the drug widely available, particularly in regions with high need.
As part of this effort, companies in Africa and India are set to manufacture generic versions of the pill. These generic alternatives could dramatically reduce costs, potentially making the medication available for as little as $5 per person per year. This move is expected to have a substantial positive impact on public health and access to essential medicines, though challenges remain regarding distribution in certain areas like Latin America.